ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Spinal Muscular Atrophy (SMA) Market Research Report 2026
Published Date: 2026-02-11
|
Report Code: QYRE-Auto-5B18414
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Drugs for Spinal Muscular Atrophy SMA Market Research Report 2024
BUY CHAPTERS

Global Drugs for Spinal Muscular Atrophy (SMA) Market Research Report 2026

Code: QYRE-Auto-5B18414
Report
2026-02-11
Pages:101
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Genentech Inc
Biogen
Ionis Pharmaceuticals

Drugs for Spinal Muscular Atrophy (SMA) Market

The global Drugs for Spinal Muscular Atrophy (SMA) market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Drugs for Spinal Muscular Atrophy (SMA) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Drugs for Spinal Muscular Atrophy (SMA) are treatments that address the genetic cause of the disease by increasing levels of the SMN (survival motor neuron) protein. Key therapies include Spinraza (nusinersen), administered via spinal injection, Zolgensma, a one-time gene therapy given through intravenous infusion, and Evrysdi (risdiplam), an oral solution taken daily.
The North American market for Drugs for Spinal Muscular Atrophy (SMA) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Drugs for Spinal Muscular Atrophy (SMA) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Drugs for Spinal Muscular Atrophy (SMA) include Novartis, Genentech, Biogen, Ionis Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Drugs for Spinal Muscular Atrophy (SMA) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Drugs for Spinal Muscular Atrophy (SMA). The Drugs for Spinal Muscular Atrophy (SMA) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Drugs for Spinal Muscular Atrophy (SMA) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Drugs for Spinal Muscular Atrophy (SMA) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Drugs for Spinal Muscular Atrophy (SMA) Market Report

Report Metric Details
Report Name Drugs for Spinal Muscular Atrophy (SMA) Market
Segment by Type
  • Oral Drugs
  • Injections
by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Genentech, Biogen, Ionis Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Drugs for Spinal Muscular Atrophy (SMA) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Drugs for Spinal Muscular Atrophy (SMA) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Drugs for Spinal Muscular Atrophy (SMA) Market report?

Ans: The main players in the Drugs for Spinal Muscular Atrophy (SMA) Market are Novartis, Genentech, Biogen, Ionis Pharmaceuticals

What are the Application segmentation covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report?

Ans: The Applications covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report?

Ans: The Types covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report are Oral Drugs, Injections

1 Drugs for Spinal Muscular Atrophy (SMA) Market Overview
1.1 Product Definition
1.2 Drugs for Spinal Muscular Atrophy (SMA) by Type
1.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type: 2025 vs 2032
1.2.2 Oral Drugs
1.2.3 Injections
1.3 Drugs for Spinal Muscular Atrophy (SMA) by Application
1.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Estimates and Forecasts
1.4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue 2021–2032
1.4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales 2021–2032
1.4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Drugs for Spinal Muscular Atrophy (SMA) Market Competition by Manufacturers
2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Types and Applications
2.7 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Entry into the Industry
2.8 Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation and Trends
2.8.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue
2.8.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Scenario by Region
3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021–2032
3.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021–2026
3.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2027–2032
3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021–2032
3.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021–2026
3.3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2027–2032
3.4 North America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.4.1 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.4.3 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.5.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.5.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021–2032)
3.6.3 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.7.1 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.7.3 Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021–2032)
4.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021–2026)
4.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027–2032)
4.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021–2032)
4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021–2032)
4.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021–2026)
4.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027–2032)
4.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021–2032)
4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021–2032)
5.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021–2026)
5.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027–2032)
5.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021–2032)
5.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021–2032)
5.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021–2026)
5.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027–2032)
5.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021–2032)
5.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Company Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Ionis Pharmaceuticals
6.4.1 Ionis Pharmaceuticals Company Information
6.4.2 Ionis Pharmaceuticals Description and Business Overview
6.4.3 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.4.5 Ionis Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Chain Analysis
7.2 Drugs for Spinal Muscular Atrophy (SMA) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process Analysis
7.4 Drugs for Spinal Muscular Atrophy (SMA) Sales and Marketing
7.4.1 Drugs for Spinal Muscular Atrophy (SMA) Sales Channels
7.4.2 Drugs for Spinal Muscular Atrophy (SMA) Distributors
7.5 Drugs for Spinal Muscular Atrophy (SMA) Customer Analysis
8 Drugs for Spinal Muscular Atrophy (SMA) Market Dynamics
8.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
8.2 Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
8.3 Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
8.4 Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
Genentech Inc
Biogen
Ionis Pharmaceuticals
List of Tables
 Table 1. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Types and Applications
 Table 12. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Drugs for Spinal Muscular Atrophy (SMA) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Drugs for Spinal Muscular Atrophy (SMA) Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2021–2026
 Table 18. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021–2026)
 Table 19. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2027–2032
 Table 20. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2027–2032)
 Table 21. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021–2026)
 Table 23. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2027–2032)
 Table 25. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
 Table 27. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
 Table 28. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
 Table 32. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
 Table 33. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
 Table 42. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
 Table 43. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2021–2026)
 Table 51. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2027–2032)
 Table 52. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021–2026)
 Table 53. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2027–2032)
 Table 54. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021–2026)
 Table 57. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2027–2032)
 Table 58. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2021–2026)
 Table 61. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2027–2032)
 Table 62. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021–2026)
 Table 63. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2027–2032)
 Table 64. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021–2026)
 Table 67. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2027–2032)
 Table 68. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2027–2032)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Novartis Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Genentech Company Information
 Table 76. Genentech Description and Business Overview
 Table 77. Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Genentech Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 79. Genentech Recent Developments/Updates
 Table 80. Biogen Company Information
 Table 81. Biogen Description and Business Overview
 Table 82. Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Biogen Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 84. Biogen Recent Developments/Updates
 Table 85. Ionis Pharmaceuticals Company Information
 Table 86. Ionis Pharmaceuticals Description and Business Overview
 Table 87. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 89. Ionis Pharmaceuticals Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Drugs for Spinal Muscular Atrophy (SMA) Distributors List
 Table 93. Drugs for Spinal Muscular Atrophy (SMA) Customers List
 Table 94. Drugs for Spinal Muscular Atrophy (SMA) Market Trends
 Table 95. Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
 Table 96. Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
 Table 97. Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Drugs for Spinal Muscular Atrophy (SMA)
 Figure 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Type: 2025 & 2032
 Figure 4. Oral Drugs Product Picture
 Figure 5. Injections Product Picture
 Figure 6. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Application: 2025 & 2032
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Other
 Figure 11. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (US$ Million), 2021–2032
 Figure 13. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), 2021–2032
 Figure 14. Global Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit), 2021–2032
 Figure 15. Drugs for Spinal Muscular Atrophy (SMA) Report Years Considered
 Figure 16. Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Manufacturers in 2025
 Figure 17. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Drugs for Spinal Muscular Atrophy (SMA) Players: Market Share by Revenue in Drugs for Spinal Muscular Atrophy (SMA) in 2025
 Figure 19. Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
 Figure 22. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
 Figure 23. United States Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
 Figure 26. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021–2032)
 Figure 34. China Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
 Figure 42. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2021–2032)
 Figure 53. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2021–2032)
 Figure 54. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2021–2032)
 Figure 56. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2021–2032)
 Figure 57. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2021–2032)
 Figure 58. Drugs for Spinal Muscular Atrophy (SMA) Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Spinal Muscular Atrophy SMA Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Injections for SMA Market Research Report 2024
Global Nusinersen Market Research Report 2024
Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024
Spinal Muscular Atrophy SMA Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Clinical Trial Capsules Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Spinal Muscular Atrophy Medicine Market Research Report 2025
Spinal and Bulbar Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bulbospinal Muscular Atrophy Drugs Market Research Report 2024
Global Spinal Muscular Atrophy Genetic Detection Market Research Report 2024
Global Multiple System Atrophy Therapeutics Market Research Report 2024
Global Musculoskeletal System Disorder Drug Market Research Report 2024
Global Geographic Atrophy Drugs Market Research Report 2024
Global Atropine Sulfate for Injection Market Research Report 2024
Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Musculoskeletal System Disorder Therapeutics Market Research Report 2024
Global Baclofe Injection Market Research Report 2024
Global Protein based Drug Market Research Report 2024
Global AAV Vector Based Gene Therapy Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions